Featured Publications
Exploiting Gene-Environment Independence for Analysis of Case–Control Studies: An Empirical Bayes-Type Shrinkage Estimator to Trade-Off Between Bias and Efficiency
Mukherjee B, Chatterjee N. Exploiting Gene-Environment Independence for Analysis of Case–Control Studies: An Empirical Bayes-Type Shrinkage Estimator to Trade-Off Between Bias and Efficiency. Biometrics 2007, 64: 685-694. PMID: 18162111, DOI: 10.1111/j.1541-0420.2007.00953.x.Peer-Reviewed Original ResearchConceptsGene-environment independenceShrinkage estimatorsLog odds ratio parametersCase-control dataGene-environment independence assumptionOdds ratio parametersCase-control estimatorsData-adaptive fashionData exampleProspective logistic regression analysisBinary exposureGene-environment associationsIndependence assumptionLogistic regression analysisCase-onlyMaximum likelihood frameworkEstimationSample sizeBinary genesRegression analysisChatterjeeExamplesWeighted averageAssumptions
2023
A framework for assessing interactions for risk stratification models: the example of ovarian cancer
Phung M, Lee A, McLean K, Anton-Culver H, Bandera E, Carney M, Chang-Claude J, Cramer D, Doherty J, Fortner R, Goodman M, Harris H, Jensen A, Modugno F, Moysich K, Pharoah P, Qin B, Terry K, Titus L, Webb P, Wu A, Zeinomar N, Ziogas A, Berchuck A, Cho K, Hanley G, Meza R, Mukherjee B, Pike M, Pearce C, Trabert B. A framework for assessing interactions for risk stratification models: the example of ovarian cancer. Journal Of The National Cancer Institute 2023, 115: 1420-1426. PMID: 37436712, PMCID: PMC10637032, DOI: 10.1093/jnci/djad137.Peer-Reviewed Original ResearchConceptsFamily history of ovarian cancerOvarian Cancer Association ConsortiumHistory of ovarian cancerFirst-degree family historyMenopausal statusRisk stratification modelCase-control studyRisk prediction modelOvarian cancerDisease riskAccurate risk stratification modelsStratification modelRisk/protective factorsDepot medroxyprogesterone acetate useProtective factorsFactor analysisRiskComprehensive analysis of interactionsCancerAcetate useUnequivocal riskStatusBreastfeedingAnalysis of interactionsPairwise interactions
2022
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery
Phung M, Webb P, DeFazio A, Fereday S, Lee A, Bowtell D, Fasching P, Goode E, Goodman M, Karlan B, Lester J, Matsuo K, Modugno F, Brenton J, Van Gorp T, Pharoah P, Schildkraut J, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, Deurloo C, Terry K, Hanley G, Pike M, Berchuck A, Ramus S, Pearce C, Consortium O. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecologic Oncology 2022, 168: 68-75. PMID: 36401943, PMCID: PMC10398872, DOI: 10.1016/j.ygyno.2022.10.018.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Ovarian EpithelialCytoreduction Surgical ProceduresFemaleHumansOvarian NeoplasmsParityPregnancyRetrospective StudiesConceptsHigh-grade serous ovarian cancerEstrogen-only therapyPrimary cytoreductive surgeryMacroscopic residual diseaseResidual diseaseParous womenFamily history of ovarian cancerOvarian Cancer Association ConsortiumMenopausal hormone therapy useHistory of ovarian cancerFirst-degree family historyCytoreductive surgeryOvarian cancer riskOvarian cancerAdvanced stage high-grade serous ovarian cancerPresence of macroscopic residual diseaseHormone therapy useHigh-grade serous ovarian cancer patientsDepot medroxyprogesterone acetate useBody mass indexLogistic regression modelsOral contraceptive useIncomplete pregnanciesSerous ovarian cancerFactors influencing survivalHigh pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival
Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharaoh P, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL. High pre-diagnosis inflammation-related risk score associated with decreased ovarian cancer survival. Cancer Epidemiology Biomarkers & Prevention 2022, 31: cebp.epi-21-0977-a.2021. PMID: 34789471, PMCID: PMC9281656, DOI: 10.1158/1055-9965.epi-21-0977.Peer-Reviewed Original ResearchConceptsOvarian cancer survivalCox proportional hazards modelProportional hazards modelCancer survivalOvarian cancerRisk scoreHazards modelNonsteroidal anti-inflammatory drug useAnti-inflammatory drug useMenopausal hormone therapy useEnvironmental tobacco smoke exposureInvasive epithelial ovarian cancerHormone therapy usePelvic inflammatory diseaseInflammation-related factorsPolycystic ovarian syndromeTobacco smoke exposureBody mass indexRisk of deathEpithelial ovarian cancerOvarian Cancer Association ConsortiumOvarian cancer diagnosisHigh death rateAspirin useOvarian syndrome
2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesEndometriosisEstrogen Replacement TherapyFemaleHumansHysterectomyMenopauseOvarian NeoplasmsConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported dataDepot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk
Phung M, Lee A, Wu A, Berchuck A, Cho K, Cramer D, Doherty J, Goodman M, Hanley G, Harris H, McLean K, Modugno F, Moysich K, Mukherjee B, Schildkraut J, Terry K, Titus L, Consortium O, Jordan S, Webb P, Consortium O, Pike M, Pearce C. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 927-935. PMID: 33619020, PMCID: PMC9281627, DOI: 10.1158/1055-9965.epi-20-1355.Peer-Reviewed Original ResearchConceptsOvarian cancer riskDepot medroxyprogesterone acetate useRisk of ovarian cancerDepot medroxyprogesterone acetateCancer riskOvarian cancerDecreased riskInverse associationRisk of invasive epithelial ovarian cancerRisk of ovarian cancer overallAssociated with decreased risk of ovarian cancerDecreased risk of ovarian cancerOvarian Cancer Association ConsortiumDecreased ovarian cancer riskSystematic reviewOvarian cancer overallInvasive epithelial ovarian cancerAssociated with decreased riskCombined oral contraceptive useInjectable progestin-only contraceptivesProgestin-only contraceptive useProgestin-releasing intrauterine deviceContraceptive useAssociated with ovarian cancerProgestin-only contraceptives
2020
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
Lee AW, Rosenzweig S, Wiensch A, Group T, Ramus SJ, Menon U, Gentry-Maharaj A, Ziogas A, Anton-Culver H, Whittemore AS, Sieh W, Rothstein JH, McGuire V, Wentzensen N, Bandera EV, Qin B, Terry KL, Cramer DW, Titus L, Schildkraut JM, Berchuck A, Goode EL, Kjaer SK, Jensen A, Jordan SJ, Ness RB, Modugno F, Moysich K, Thompson PJ, Goodman MT, Carney ME, Chang-Claude J, Rossing MA, Harris HR, Doherty JA, Risch HA, Khoja L, Alimujiang A, Phung MT, Brieger K, Mukherjee B, Pharoah PDP, Wu AH, Pike MC, Webb PM, Pearce CL. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal Of The National Cancer Institute 2020, 113: 301-308. PMID: 32766851, PMCID: PMC7936053, DOI: 10.1093/jnci/djaa099.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive epithelial ovarian cancerClear cell ovarian cancerIncomplete pregnanciesEpithelial ovarian cancerOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioInvasive epithelial ovarian cancer casesEpithelial ovarian cancer casesHistotype-specific analysesHistotype-specific associationsOral contraceptive useInvasive ovarian cancerHistory of breastfeedingConfidence intervalsOvarian cancer casesCase-control studyOCAC studiesMajor histotypesPooled analysisInverse associationCancer casesComplete pregnancyMenopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival
Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A, Anton-Culver H, Anglesio MS, Bandera EV, Berchuck A, Bowtell DDL, Chenevix-Trench G, Cho KR, Cramer DW, DeFazio A, Doherty JA, Fortner RT, Garsed DW, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Høgdall E, Huntsman DG, Shen H, Jensen A, Johnatty SE, Jordan SJ, Kjaer SK, Kupryjanczyk J, Lambrechts D, McLean K, Menon U, Modugno F, Moysich K, Ness R, Ramus SJ, Richardson J, Risch H, Rossing MA, Trabert B, Wentzensen N, Ziogas A, Terry KL, Wu AH, Hanley GE, Pharoah P, Webb PM, Pike MC, Pearce CL, Consortium F. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology 2020, 158: 702-709. PMID: 32641237, PMCID: PMC7487048, DOI: 10.1016/j.ygyno.2020.06.481.Peer-Reviewed Original ResearchConceptsMenopausal hormone therapyOvarian cancer survivalMHT useResidual diseaseHormone therapyCancer survivalOvarian cancerHigh-grade serous carcinomaMacroscopic residual diseaseHormone therapy useFavorable prognostic factorPost-menopausal womenOvarian Cancer Association ConsortiumProportional hazards modelRecency of useImproved survivalPrognostic factorsTherapy useSerous carcinomaOvarian carcinomaHazards modelSmall studyAdvanced stageLarger studyLogistic regressionEstrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.
Lee A, Wu A, Wiensch A, Mukherjee B, Terry K, Harris H, Carney M, Jensen A, Cramer D, Berchuck A, Doherty J, Modugno F, Goodman M, Alimujiang A, Rossing M, Cushing-Haugen K, Bandera E, Thompson P, Kjaer S, Hogdall E, Webb P, Huntsman D, Moysich K, Lurie G, Ness R, Stram D, Roman L, Pike M, Pearce C. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. Epidemiology 2020, 31: 402-408. PMID: 32028322, PMCID: PMC7584395, DOI: 10.1097/ede.0000000000001175.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesEstrogen Replacement TherapyFemaleHumansOvarian NeoplasmsRisk AssessmentConceptsRisk of ovarian cancerEstrogen-progestin combined therapyEstrogen-alone therapyAssociated with increased riskOvarian cancerCombination therapyRisk of ovarian cancer overallAssociated with increased risk of ovarian cancerOvarian cancer risk factorsPopulation-based case-control studyOvarian Cancer Association ConsortiumMenopausal hormone therapy useIncreased risk of endometrial cancerOvarian cancer overallRisk of endometrial cancerCancer risk factorsHistotypes of ovarian cancerRisk factorsProgestin hormone therapyMucinous ovarian cancerOvarian cancer casesIn-person interviewsHormone therapy useOvarian cancer histotypesCase-control study
2019
A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants
Kim S, Wang M, Tyrer J, Jensen A, Wiensch A, Liu G, Lee A, Ness R, Salvatore M, Tworoger S, Whittemore A, Anton‐Culver H, Sieh W, Olson S, Berchuck A, Goode E, Goodman M, Doherty J, Chenevix‐Trench G, Rossing M, Webb P, Giles G, Terry K, Ziogas A, Fortner R, Menon U, Gayther S, Wu A, Song H, Brooks‐Wilson A, Bandera E, Cook L, Cramer D, Milne R, Winham S, Kjaer S, Modugno F, Thompson P, Chang‐Claude J, Harris H, Schildkraut J, Le N, Wentzensen N, Trabert B, Høgdall E, Huntsman D, Pike M, Pharoah P, Pearce C, Mukherjee B. A comprehensive gene–environment interaction analysis in Ovarian Cancer using genome‐wide significant common variants. International Journal Of Cancer 2019, 144: 2192-2205. PMID: 30499236, PMCID: PMC6399057, DOI: 10.1002/ijc.32029.Peer-Reviewed Original ResearchConceptsOral contraceptive pill useExcess risk due to additive interactionOvarian cancer risk factorsOral contraceptive pillsGene-environment interaction analysisCancer risk factorsGene-environment analysisOvarian cancer casesOCP useCase-control studyGenome-wide association analysisAdditive scaleCancer casesOvarian cancerOdds ratioCommon variantsDuration of OCP useRisk allelesRisk factorsGenetic variantsAdditive interactionAssociation analysisWomenFollow-upC allele
2016
A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer
Lee A, Bomkamp A, Bandera E, Jensen A, Ramus S, Goodman M, Rossing M, Modugno F, Moysich K, Chang‐Claude J, Rudolph A, Gentry‐Maharaj A, Terry K, Gayther S, Cramer D, Doherty J, Schildkraut J, Kjaer S, Ness R, Menon U, Berchuck A, Mukherjee B, Roman L, Pharoah P, Chenevix‐Trench G, Olson S, Hogdall E, Wu A, Pike M, Stram D, Pearce C, Consortium F. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal Of Cancer 2016, 139: 2646-2654. PMID: 27420401, PMCID: PMC5500237, DOI: 10.1002/ijc.30274.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAllelesAlternative SplicingCase-Control StudiesDisease SusceptibilityEstrogen Replacement TherapyFemaleGene-Environment InteractionGenome-Wide Association StudyGenotypeHumansMenopauseMiddle AgedOdds RatioOvarian NeoplasmsPolymorphism, Single NucleotidePopulation SurveillanceRiskTelomeraseConceptsOvarian Cancer Association ConsortiumEstrogen-alone therapyOvarian cancer riskEndometrioid ovarian cancerOvarian cancerET usersET useT alleleAssociated with ovarian cancer riskCancer riskLong-term ET usersOvarian cancer susceptibility lociRisk of ovarian cancerSusceptibility variantsMenopausal estrogen therapyCancer susceptibility lociSerous ovarian cancerSplice variantsNon-usersCase-control studyConditional logistic regressionGenome-wide association studiesIncreased risk of diseaseEndometrioid histotypeEstrogen therapy
2007
Semiparametric Bayesian Analysis of Case–Control Data under Conditional Gene-Environment Independence
Mukherjee B, Zhang L, Ghosh M, Sinha S. Semiparametric Bayesian Analysis of Case–Control Data under Conditional Gene-Environment Independence. Biometrics 2007, 63: 834-844. PMID: 17489972, DOI: 10.1111/j.1541-0420.2007.00750.x.Peer-Reviewed Original ResearchConceptsGene-environment independenceSemiparametric Bayesian approachTraditional logistic regression analysisParametric model assumptionsSemiparametric Bayesian modelCase-control studyPopulation-based case-control studySimulation studyBayesian approachRobust alternativeLogistic regression analysisUnderlying populationEfficient estimation techniqueBayesian modelEnvironmental exposuresModel assumptionsScientific evidenceRegression analysisAssociated with diseaseEstimation techniquesOvarian cancerControl populationPopulationIndependenceCovariates